Energenesis Biomedical CO.,LTD. (TPE:6657)

Market Cap	4.06B -39.1%
Revenue (ttm)	7.67M -1.0%
Net Income	-258.40M
EPS	-2.92
Shares Out	87.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	868,627
Average Volume	343,788
Open	48.45
Previous Close	49.65
Day's Range	46.05 - 48.45
52-Week Range	39.75 - 76.50
Beta	0.53
RSI	55.13
Earnings Date	May 8, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 35
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6657

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.